Novo Nordisk 29. Apr. 2026 Novo Nordisk faces competition from Canadian generic version of Ozempic - medwatch.com
Novo Nordisk 28. Apr. 2026 Novo Holdings makes 1st commitment to Korean PEF as global pharma capital targets K-bio - KED Global
Novo Nordisk 27. Apr. 2026 The 10 Most Influential Health and Life Science Companies of 2026 - Time Magazine
Novo Nordisk 23. Apr. 2026 With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide - Fierce Pharma
Novo Nordisk 20. Apr. 2026 Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory - Yahoo
Novo Nordisk 20. Apr. 2026 Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme - TipRanks
Novo Nordisk 20. Apr. 2026 Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win - Fierce Biotech
Novo Nordisk 20. Apr. 2026 Novo posts trial win for sickle cell disease drug (NVO:NYSE) - Seeking Alpha
Novo Nordisk 20. Apr. 2026 Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory - Clinical Trials Arena
Novo Nordisk 17. Apr. 2026 Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. - Investor's Business Daily